Upregulation of Bcl-2 Confers Resistance to FLT3 Inhibition in FLT3ITD AML with Secondary Acquired Mutations

被引：3

作者：

Yamatani, Kotoko ^{[1
]}

Tabe, Yoko ^{[2
,3
,4
]}

Saito, Kaori ^{[1
]}

Yang, Haeun ^{[1
,5
]}

Murakami-Tonami, Yuko ^{[1
]}

Suzuki, Koya ^{[1
,6
]}

Zhang, Weiguo ^{[7
]}

Kinjo, Sonoko ^{[8
]}

Ikeo, Kazuho ^{[8
]}

Mogushi, Kaoru ^{[9
,10
]}

Hosoya, Masaki ^{[10
,11
]}

Yamaguchi, Shigeo ^{[11
]}

Harada, Hironori ^{[12
]}

Miida, Takashi ^{[1
]}

Shah, Neil P. ^{[13
]}

Konopleva, Marina Y. ^{[14
]}

Hayashizaki, Yoshihide ^{[15
]}

Andreeff, Michael ^{[14
]}

机构：

[1] Juntendo Univ, Grad Sch Med, Dept Clin Lab Med, Tokyo, Japan

[2] Juntendo Univ, Dept Clin Lab Med, Sch Med, Tokyo, Japan

[3] Juntendo Univ, Grad Sch Medcine, Dept Next Generat Hematol Lab Med, Tokyo, Japan

[4] Univ Texas MD Anderson Canc Ctr, Sect Mol Hematol & Therapy, Dept Leukemia, Houston, TX 77030 USA

[5] Juntendo Univ, Grad Sch Med, Leading Ctr Dev & Res Canc Med, Tokyo, Japan

[6] Juntendo Univ, Res Inst Dis Old Age, Grad Sch Med, Tokyo, Japan

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[8] Natl Inst Genet, Ctr Informat Biol, Shizuoka, Japan

[9] Juntendo Univ, Grad Sch Med, Dept Diagnost & Therapeut Intractable Dis, Tokyo, Japan

[10] Juntendo Univ, Grad Sch Med, Intractable Dis Res Ctr, Tokyo, Japan

[11] Juntendo Univ, Sch Med, Dept Oncol, Tokyo, Japan

[12] Juntendo Univ, Grad Sch Med, Dept Hematol, Tokyo, Japan

[13] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA 94143 USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Sect Leukemia Biol Res, Houston, TX 77030 USA

[15] RIKEN, Ctr Life Sci Technoligies, Prevent Med & Diag Innovat Program, Yokohama, Kanagawa, Japan

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-109957

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3944

引用

页数：2

共 50 条

[31] The Response of FLT3/ITD AML to FLT3 Inhibition: Apoptosis of Peripheral Blood Blasts and Differentiation of Bone Marrow Blasts
Sexauer, Amy
Yang, Xiaochuan
Perl, Alexander E.
Thiede, Christian
Borowitz, Michael J.
Levis, Mark J.
BLOOD, 2011, 118 (21) : 429 - 430
[32] Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
Christoph Rummelt
Sivahari P. Gorantla
Manja Meggendorfer
Anne Charlet
Cornelia Endres
Konstanze Döhner
Florian H. Heidel
Thomas Fischer
Torsten Haferlach
Justus Duyster
Nikolas von Bubnoff
Leukemia, 2021, 35 : 2017 - 2029
[33] Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
Rummelt, C.
Gorantla, S. P.
Endres, C.
Doehner, K.
Meggendorfer, M.
Heidel, F.
Fischer, T.
Haferlach, T.
Duyster, J.
von Bubnoff, N.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 169 - 169
[34] Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo
Rummelt, Christoph
Gorantla, Sivahari P.
Meggendorfer, Manja
Charlet, Anne
Endres, Cornelia
Doehner, Konstanze
Heidel, Florian H.
Fischer, Thomas
Haferlach, Torsten
Duyster, Justus
von Bubnoff, Nikolas
LEUKEMIA, 2021, 35 (07) : 2017 - 2029
[35] Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML
Melgar, Katelyn
Walker, MacKenzie
Jiang, Jian-kang
Wilson, Kelli
Mulloy, James C.
Thomas, Craig J.
Starczynowski, Daniel T.
BLOOD, 2015, 126 (23)
[36] FLT3 Inhibitor Treatment Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CAR-T Cells
Jetani, Hardikkumar
Garcia-Cadenas, Irene
Nerreter, Thomas
Goetz, Ralph
Sierra, Jorge
Bonig, Halvard
Sauer, Markus
Einsele, Hermann
Hudecek, Michael
BLOOD, 2018, 132
[37] Role of Enhanced Autophagy in Resistance of FLT3-ITD AML Stem Cells to FLT3 TKI Treatment
Qiu, Shaowei
Paterson, Andrew J.
Abraham, Ajay
He, Jianbo
Shah, Mansi
Agarwal, Puneet
Mullen, Amanda K.
Li, Hui
Harris, Mason W.
Anderson, Nicholas R.
Bhatia, Ravi
BLOOD, 2018, 132
[38] Developing dual FLT3/MNK inhibitors to overcome sorafenib resistance in FLT3-ITD AML cells
Zhao, Linxiang
Zuo, Shuwei
Xing, Kun
Yue, Xiaoshuang
Zhang, Huimin
Zhang, Jingyi
Waxman, Samuel
Jing, Yongkui
CANCER RESEARCH, 2024, 84 (06)
[39] FLT3 Inhibitor Treatment in FLT3-Mutated AML Is Associated with Development of Secondary FLT3-TKD Mutations
Alvarado, Yesid
Kantarjian, Hagop M.
Ravandi, Farhad
Luthra, Rajyalakshmi
Borthakur, Gautam
Manero, Guillermo Garcia
Faderl, Stefan
Konopleva, Marina
Estrov, Zeev
Andreeff, Michael
Cortes, Jorge E.
BLOOD, 2011, 118 (21) : 648 - 648
[40] Flt3/ITD Confers Resistance to FLT3 Inhibitor AC220 By up-Regulating Runx1
Hirade, Tomohiro
Abe, Mariko
Onishi, Chie
Yamaguchi, Seiji
Fukuda, Seiji
BLOOD, 2014, 124 (21)

← 1 2 3 4 5 →